Literature DB >> 25090752

[High prevalence of proteinuric nephropathy screened in patients with type 2 diabetes consulting community-based general practitioners in French overseas departments and territories. ALBUM study].

Xavier Debussche, Maryse Pholsena, Alain Fournier, Pauline Kangambega, Jean-Marc Gabriel, Carine Hénin, Mohamed Meddeb, Franck Semel, Yogananda Thirapathi-Appadu, Michèle Vado-Prudent, Violaine Emal-Aglae.   

Abstract

UNLABELLED: OBJECTIVE,
METHOD: Chronic kidney disease is a major public health problem. This observational epidemiological study aimed to evaluate the prevalence of proteinuric nephropathy in patients with type 2 diabetes consulting a community-based general practitioner in French overseas departments and territories (DOM-TOM). Screening was carried out with reagent strips Albustix for proteinuria and, in case of trace amounts or a negative result, Microalbustix for microalbuminuria.
RESULTS: 91 general practitioners participated in the study with 402 evaluable patients (54% female, mean age 60.1 +/- 11.2 years). The duration of diabetes was 8.9 +/- 6.6 years and mean HbA1c was 7.3 +/- 1.4% (52.2% with HbA1c < or = 7%). Screening was positive for 45.7% of the patients: 23.6% positive for proteinuria with Albustix [95% CI: 19.5-27.8] and 22.1% with Microalbustix.
CONCLUSION: Screening with reagent strips revealed that nearly half the patients had proteinuria or albuminuria, thus confirming the high prevalence of nephropathy in type 2 diabetes patients living in the Dom-Tom and illustrating the need for frequent renal function screening in type 2 diabetics in general medicine for the prevention of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25090752

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  1 in total

1.  Health literacy in context: struggling to self-manage diabetes - a longitudinal qualitative study.

Authors:  Xavier Debussche; Maryvette Balcou-Debussche; Delphine Ballet; Jessica Caroupin-Soupoutevin
Journal:  BMJ Open       Date:  2022-06-14       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.